ARTBIO

ARTBIO is a biotechnology company developing a new class of alpha radioligand therapies to redefine cancer care. The company is building an ecosystem — from targeted radioligand drug candidates and radiochemistry to manufacturing, clinical infrastructure, and partnerships — to maximize the potential of these potent targeted therapies. ARTBIO aims to accelerate development and broaden patient access by combining precision targeting, specialized delivery, and collaborative clinical programs.